EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Development of a nalmefene formulation suitable for a community‐use auto‐injector

Alessandra Cipriano iD, Manjunath S Shet, Hugh Huang, Ronnie Ortiz, Garth T Whiteside, Glen Apseloff, Stephen C Harris iD

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70685 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Alessandra Cipriano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Knoa Pharma LLC, Stamford, Connecticut, USA. Hauptthemen laut MEDLINE: Analgesics, Opioid, Naltrexone, Narcotic Antagonists, Respiratory Insufficiency. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Knoa Pharma LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Time to onset of reversal is critical when treating opioid‐induced respiratory depression and hypoxia. This study aimed to develop a formulation of the opioid antagonist nalmefene with an increased absorption rate and reduced time to onset of reversal following intramuscular administration.

Methods

Several absorption enhancers were screened in rats, followed by confirmatory studies in dogs. Subsequently, nalmefene formulations with a range of MgCl 2 concentrations were evaluated in a two‐part translational clinical study in healthy participants. In Part 1 ( N = 17), pharmacokinetic parameters were assessed following intramuscular injections of nalmefene formulated with MgCl 2 (0.47%–4.7%) or NaCl (0.9%). In Part 2 ( N = 6), participants received intravenous fentanyl to produce opioid‐induced respiratory depression. They were then dosed with intramuscular nalmefene formulated with 0.94% MgCl 2 , intranasal naloxone or placebo (intramuscular saline) in a randomized six‐period crossover sequence with each treatment administered on two separate occasions. Minute ventilation, oxygen saturation and carbon dioxide were monitored continuously, and pharmacokinetic and pharmacodynamic parameters were evaluated.

Results

Pharmacokinetic profiles from animals indicated that MgCl 2 within a range of concentrations enhanced the nalmefene absorption rate. In the clinical studies, a nalmefene 1.5 mg formulation containing 0.94% MgCl 2 demonstrated more rapid absorption compared with a formulation containing 0.9% NaCl and also produced faster, more robust reversal of opioid‐induced respiratory depression compared with intranasal naloxone.

Conclusion

These preclinical and clinical studies demonstrate that a nalmefene formulation containing magnesium chloride produced more rapid nalmefene absorption after intramuscular injection, which is advantageous for the treatment of opioid overdose in settings where life support is not immediately available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidNaltrexoneNarcotic AntagonistsRespiratory InsufficiencyAdultAnimalsDogsFemaleHumansMaleRatsYoung AdultAdministration, IntranasalCross-Over StudiesFentanylInjections, IntramuscularNaloxoneRats, Sprague-DawleyAdolescent

Stichwörter der Autor:innen

absorptionanimal modelsclinical pharmacologyemergency medicineopioids

Substanzen

Analgesics, OpioidFentanylnalmefeneNaloxoneNaltrexoneNarcotic Antagonists

Autor:innen und Institutionen

  • Knoa Pharma LLC, Stamford, Connecticut, USA.
  • Elacon LLC, Princeton, New Jersey, USA.
  • Ohio Clinical Trials LLC, Columbus, Ohio, USA.

ORCID-Profile: Alessandra Cipriano, Stephen C Harris

Förderung

  • Knoa Pharma LLC

Zitieren

APA

Cipriano, A., Shet, M. S., Huang, H., Ortiz, R., Whiteside, G. T., Apseloff, G., & Harris, S. C. (2026). Development of a nalmefene formulation suitable for a community‐use auto‐injector. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70685

Vancouver

Cipriano A, Shet MS, Huang H, Ortiz R, Whiteside GT, Apseloff G, et al. Development of a nalmefene formulation suitable for a community‐use auto‐injector. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70685

BibTeX
@article{Cipriano2026,
  author = {Cipriano, Alessandra and Shet, Manjunath S and Huang, Hugh and Ortiz, Ronnie and Whiteside, Garth T and Apseloff, Glen and Harris, Stephen C},
  title = {Development of a nalmefene formulation suitable for a community‐use auto‐injector},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70685}
}
Kostenlos starten →